Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec;11(4):445-59.
doi: 10.1007/s13181-015-0490-z.

Purple Glove Syndrome after Phenytoin or Fosphenytoin Administration: Review of Reported Cases and Recommendations for Prevention

Affiliations
Review

Purple Glove Syndrome after Phenytoin or Fosphenytoin Administration: Review of Reported Cases and Recommendations for Prevention

Lyudmila A Garbovsky et al. J Med Toxicol. 2015 Dec.

Abstract

The aim of our study was to identify all previously reported cases of phenytoin- or fosphenytoin-associated purple glove syndrome (PGS) and summarize the most current understanding of the pathophysiology, clinical presentation, diagnosis, and treatment of the disease. We searched the English language references from MEDLINE, EMBASE, CINAHL, TOXNET, and gray literature that featured one or more case descriptions of phenytoin- or fosphenytoin-associated PGS after administration and provided information on the clinical setting of the event and associated outcome(s). Descriptive statistics were employed to summarize relevant facts about the cases. We identified 82 unique cases of parenteral phenytoin-associated PGS and 5 cases of fosphenytoin-associated PGS that were published from 1984 to 2015. Additionally, we found two cases of PGS associated with oral formulation of phenytoin published from 1999 to 2015. The spectrum of tissue injury ranged from mild local cutaneous reactions around the infusion site to frank limb ischemia. Just over a half of cases reported symptoms after one dose of IV phenytoin. Pathologic findings included evidence for microvascular thrombosis and possible microvascular or subclinical extravasation as a contributing mechanism. Dopper ultrasound and conventional angiography were used in some patients to identify arterial or venous thrombosis. Various treatments were documented including the use of supportive care such as limb elevation and heat or cold application, utilization of systemic antibiotics, anticoagulants, or vasodilators, and local infiltration of hyaluronidase, heparin, or other compounds. In a small number of patients, invasive interventions such as regional anesthesia, thrombectomy, fasciotomy, and debridement were described. Time to resolution varied from days to weeks. Resolution of PGS without deficits was documented in the majority of cases. Skin changes followed by sensory and motor deficits were described in 16, 6, and 5 cases, respectively. Four patients underwent skin grafting and eight patients required limb amputation. Death as a result of PGS was documented in two patients. PGS associated with oral and injectable phenytoin or parenteral fosphenytoin has been documented in the literature and sometimes includes significant vascular thrombosis and potentially limb-threatening ischemia. Avoidance of small hand veins, adherence to recommended IV administration guidelines and monitoring of the infusion site for reactions should be considered to decrease the morbidity of IV phenytoin or fosphenytoin use. Patients with PGS and evidence of decreased distal perfusion should undergo prompt vascular imaging and potential intervention to avoid ischemic sequelae. Alternative anticonvulsant drugs should be considered in patients at risk for PGS when possible.

Keywords: Adverse drug events; Emergency services; Forearm injuries; Fosphenytoin; Hand injuries; Phenytoin; Purple glove syndrome; Vascular injuries.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Photograph of patient’s hands 2 h after intravenous infusion of undiluted phenytoin 250 mg infused using Baxa Microfuse® Infuser over 15 min through a 20-gauge peripheral intravenous catheter in the dorsal left proximal thumb at a rate not exceeding 25 mg/min. Left hand with diminished perfusion, skin pallor, and dusky and cyanotic nailbeds
Fig. 2
Fig. 2
Photograph of patient’s hands 4 h after intravenous infusion of undiluted phenytoin 250 mg. Progression of ischemia to sensory loss and paralysis of left hand. Left hand and fingers with extensive pallor and cyanosis
Fig. 3
Fig. 3
CT angiography of the left upper extremity performed after loss of left distal pulses obtained 20 h after intravenous infusion of undiluted phenytoin 250 mg. Proximal ulnar artery and distal radial artery occlusion with no run-off to the hand. Edema of the multiple muscle compartments and soft tissues in the forearm and hand, reflecting ischemia. Several foci of gas in the palmar aspect of the hand, concerning for necrosis

References

    1. Parenteral Dilantin (Phenytoin Sodium Injection, USP) [prescribing information]. Revised February 2013. Parke Davis: New York. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/010151s037lbl.pdf. Accessed 6 June 2015.
    1. Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348–55. doi: 10.1111/j.1468-1331.2009.02917.x. - DOI - PubMed
    1. Cerebyx (Fosphenytoin Sodium Injection) [prescribing information]. Pfizer Labs: New York. Revised April 2014. http://labeling.pfizer.com/ShowLabeling.aspx?id=749. Accessed 6 June 2015.
    1. Comer J. Extravasation from intravenous phenytoin. Am J Intraven Ther Clin Nutr. 1984;11:23–9.
    1. Hanna D. Purple glove syndrome: a complication of intravenous phenytoin. J Neurosci Nurs. 1992;24(6):340–5. doi: 10.1097/01376517-199212000-00011. - DOI - PubMed

LinkOut - more resources